MedTrace Logo

Domperidone in Refractory Gastroparesis

NCT00760461 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2017-08-18

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to prescribe oral domperidone for patients with gastroparesis who have failed or suffered adverse effects from standard medical therapy.

Conditions

Interventions

DRUG

Domperidone

10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Anish A Sheth, MD · Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760461 on ClinicalTrials.gov